Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

Also called NCT01516723

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 330 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01516723
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01516723. Randomized; single masking; primary purpose treatment. Start 2012-02 (actual); primary completion 2016-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
Acronym
PRISON-IV
Condition
Coronary Disease
Condition
Coronary Stenosis
Intervention (Device)
Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Lead sponsor
R&D Cardiologie (class: other)
Collaborator
Biotronik SE & Co. KG (class: industry)

Record details

Record id
cardio:ct-nct01516723
Content hash
d99d1901c700ec60cea53cfb5edf5d235a1948002aa9dca4fd88a05226cb6a7a